Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cue Biopharma Inc CUE

Healthcare Biotechnology
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease... see more

Recent & Breaking News (NDAQ:CUE)

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire May 16, 2019

Cue Biopharma Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, CUE-101, in Treatment of HPV-driven Cancers

GlobeNewswire May 16, 2019

Dr. Anish Suri, Cue Biopharma's CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference

GlobeNewswire May 9, 2019

Cue Biopharma to Present Corporate Overview and Update at the Oppenheimer 29th Annual Healthcare Conference

GlobeNewswire March 14, 2019

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire March 7, 2019

Cue Biopharma to Present Corporate Update at 2019 BIO CEO & Investor Conference

GlobeNewswire February 11, 2019

Cue Biopharma Announces Presentation Highlighting Immuno-STAT Platform and CUE-101 at the 2019 Keystone Symposia Conference

GlobeNewswire January 16, 2019

Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT™ Target in Oncology

GlobeNewswire December 20, 2018

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire November 14, 2018

Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

GlobeNewswire November 9, 2018

Cue Biopharma Announces Strategic Collaboration with LG Chem Life Sciences for Immuno-STAT™ Biologics in Oncology

GlobeNewswire November 8, 2018

Cue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

GlobeNewswire October 30, 2018

Dr. Anish Suri, Cue Biopharma’s CSO, to Present at Upcoming Precision: Lung Cancer Summit

GlobeNewswire October 24, 2018

Cue Biopharma Announces Strategic Research Collaboration with Albert Einstein College of Medicine to Further the Potential of Immuno-STAT™ Platform in Chronic Infectious Diseases

GlobeNewswire October 17, 2018

Cue Biopharma Appoints Hon. Randall R. Rader to Chair Company’s Intellectual Property Committee

GlobeNewswire October 3, 2018

Cue Biopharma to Host Investor Business Update Call and Webcast

GlobeNewswire August 14, 2018

Cue Biopharma Adds Frank Morich, M.D., Ph.D. to Board of Directors

GlobeNewswire August 3, 2018

Cue Biopharma Appoints Bethany Mancilla as Chief Business Officer and Senior Vice President

GlobeNewswire July 24, 2018

Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck

GlobeNewswire July 12, 2018

Cue Biopharma Strengthens Board of Directors with Addition of Fred Driscoll to Chair Audit Committee

GlobeNewswire June 28, 2018